Literature DB >> 23077435

Consent timing and experience: modifiable factors that may influence interest in clinical research.

David E Gerber1, Drew W Rasco, Celette Sugg Skinner, Jonathan E Dowell, Jingsheng Yan, Jennifer R Sayne, Yang Xie.   

Abstract

PURPOSE: Low rates of participation in cancer clinical trials have been attributed to patient, institutional, and study characteristics. However, few studies have examined factors related to the consent process. We therefore evaluated the impact of consent timing and experience on markers of patient interest in research.
METHODS: We performed a retrospective analysis of patients enrolled in a cancer center tissue repository. During enrollment, patients were asked if they were willing to be contacted in the future to provide medical follow-up information and/or to participate in other clinical research. We analyzed the association between patient responses to these questions and consent process factors using univariate analysis and multivariate logistic regression.
RESULTS: Of 922 patients evaluated, 85% agreed to be contacted to provide follow-up information, and 83% agreed to be contacted to participate in future research studies. In univariate analysis, willingness to be contacted for future research was associated with consenter experience (P = .01) and had a trend toward association with the timing of enrollment in relation to diagnosis (P = .08), but it was not associated with patient sex, race, or diagnosis. In multivariate analysis, responses remained associated with consenter experience (P = .02).
CONCLUSION: Factors related to the consent process, including consenter experience and timing of study enrollment, are significantly associated with or have a trend toward association with markers of patient interest in clinical research. These understudied and potentially modifiable variables warrant further evaluation.

Entities:  

Year:  2011        PMID: 23077435      PMCID: PMC3457835          DOI: 10.1200/JOP.2011.000335

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  29 in total

1.  Viability of cancer clinical research: patient accrual, coverage, and reimbursement. American Medical Association Council on Scientific Affairs.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1991-02-20       Impact factor: 13.506

2.  Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study.

Authors:  Anjali S Advani; Benjamin Atkeson; Carrie L Brown; Bercedis L Peterson; Laura Fish; Jeffrey L Johnson; Jon P Gockerman; Marc Gautier
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

3.  Research consent forms: continued unreadability and increasing length.

Authors:  M E LoVerde; A V Prochazka; R L Byyny
Journal:  J Gen Intern Med       Date:  1989 Sep-Oct       Impact factor: 5.128

4.  Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.

Authors:  P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

5.  Factors that influence African-Americans' willingness to participate in medical research studies.

Authors:  V L Shavers; C F Lynch; L F Burmeister
Journal:  Cancer       Date:  2001-01-01       Impact factor: 6.860

6.  African Americans' views on research and the Tuskegee Syphilis Study.

Authors:  V S Freimuth; S C Quinn; S B Thomas; G Cole; E Zook; T Duncan
Journal:  Soc Sci Med       Date:  2001-03       Impact factor: 4.634

7.  Lay patient navigator program implementation for equal access to cancer care and clinical trials: essential steps and initial challenges.

Authors:  Michael L Steinberg; Allen Fremont; David C Khan; David Huang; Herschel Knapp; Deborah Karaman; Nell Forge; Keith Andre; Lisa M Chaiken; Oscar E Streeter
Journal:  Cancer       Date:  2006-12-01       Impact factor: 6.860

8.  Potential research participants' views regarding researcher and institutional financial conflicts of interest.

Authors:  S Y H Kim; R W Millard; P Nisbet; C Cox; E D Caine
Journal:  J Med Ethics       Date:  2004-02       Impact factor: 2.903

9.  Influence of clinical communication on patients' decision making on participation in clinical trials.

Authors:  Terrance L Albrecht; Susan S Eggly; Marci E J Gleason; Felicity W K Harper; Tanina S Foster; Amy M Peterson; Heather Orom; Louis A Penner; John C Ruckdeschel
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

10.  Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.

Authors:  Lilia Talarico; Gang Chen; Richard Pazdur
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

View more
  12 in total

1.  Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.

Authors:  Andrew L Laccetti; Sandi L Pruitt; Lei Xuan; Ethan A Halm; David E Gerber
Journal:  J Natl Cancer Inst       Date:  2015-02-09       Impact factor: 13.506

2.  Conceptual Model for Accrual to Cancer Clinical Trials.

Authors:  Simon J Craddock Lee; Caitlin C Murphy; Ann M Geiger; David E Gerber; John V Cox; Rasmi Nair; Celette Sugg Skinner
Journal:  J Clin Oncol       Date:  2019-06-05       Impact factor: 44.544

3.  Impact of prior cancer on eligibility for lung cancer clinical trials.

Authors:  David E Gerber; Andrew L Laccetti; Lei Xuan; Ethan A Halm; Sandi L Pruitt
Journal:  J Natl Cancer Inst       Date:  2014-09-24       Impact factor: 13.506

4.  Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.

Authors:  Sandra Garcia; Ajit Bisen; Jingsheng Yan; Xian-Jin Xie; Suresh Ramalingam; Joan H Schiller; David H Johnson; David E Gerber
Journal:  J Thorac Oncol       Date:  2017-08-09       Impact factor: 15.609

5.  Resolving Rivalries and Realigning Goals: Challenges of Clinical and Research Multiteam Systems.

Authors:  David E Gerber; Torsten Reimer; Erin L Williams; Mary Gill; Laurin Loudat Priddy; Deidi Bergestuen; Joan H Schiller; Haskell Kirkpatrick; Simon J Craddock Lee
Journal:  J Oncol Pract       Date:  2016-09-30       Impact factor: 3.840

6.  Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials.

Authors:  Sandra Garcia; Jessica M Saltarski; Jingsheng Yan; Xian-Jin Xie; David E Gerber
Journal:  Clin Lung Cancer       Date:  2017-05-08       Impact factor: 4.785

7.  Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations.

Authors:  David E Gerber; Ashley M Lakoduk; Laurin L Priddy; Jingsheng Yan; Xian-Jin Xie
Journal:  Oncologist       Date:  2015-05-27

8.  Cancer patient perceptions about biobanking and preferred timing of consent.

Authors:  Kathryn L Braun; Joann U Tsark; Amy Powers; Kristen Croom; Robert Kim; Francine C Gachupin; Paul Morris
Journal:  Biopreserv Biobank       Date:  2014-04       Impact factor: 2.300

9.  QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care.

Authors:  Tri Le; Hui Yang; Sawsan Rashdan; Mark S Link; Vlad G Zaha; Carlos Alvarez; David E Gerber
Journal:  Clin Lung Cancer       Date:  2019-11-25       Impact factor: 4.785

10.  Clinician Variation in Ordering and Completion of Low-Dose Computed Tomography for Lung Cancer Screening in a Safety-Net Medical System.

Authors:  David E Gerber; Heidi A Hamann; Olivia Dorsey; Chul Ahn; Jessica L Phillips; Noel O Santini; Travis Browning; Cristhiaan D Ochoa; Joyce Adesina; Vijaya Subbu Natchimuthu; Eric Steen; Harris Majeed; Amrit Gonugunta; Simon J Craddock Lee
Journal:  Clin Lung Cancer       Date:  2020-12-11       Impact factor: 4.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.